Formulation Development
Microbiotica Announces First Patient Dosed in its Phase 1b Trial of a Precision Microbiome Medicine in Ulcerative Colitis Patients
Microbiotica recently announced the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This international…
BioNTech to Acquire Biotheus to Boost Oncology Strategy
BioNTech SE and Biotheus recently announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and…
Nippon Shinyaku & Atsena Therapeutics Enter Exclusive Strategic Collaboration
Nippon Shinyaku Co., Ltd. and Atsena Therapeutics, Inc. have entered into an exclusive license agreement for the commercialization of ATSN-101 in the territory of the…
Entero Therapeutics Announces Proposed Reverse Merger With Journey Therapeutics
Entero Therapeutics, Inc. recently announced it has entered into a binding term sheet for a reverse merger transaction with Journey Therapeutics, Inc. Upon completion of…
CAR T Cell Therapies to Pave Way for Drug-Free Remission in Lupus Care
Bristol Myers Squibb and Cabaletta Bio are set to present promising Phase 1 data on CD19-directed CAR T therapies for severe, refractory lupus at the…
Kane Biotech Announces Agreement to Acquire FB Dermatology
Kane Biotech Inc. recently announced it has entered into a binding term sheet setting out the key terms and conditions relating to the acquisition of…
Attralus Therapeutic AT-02 Receives Orphan Drug Designation for the Treatment of ATTR Amyloidosis
Attralus, Inc. recently announced the US FDA has granted orphan drug designation for AT-02 for the treatment of transthyretin-associated amyloidosis (ATTR), a rare, progressive, debilitating…
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease
Zenas BioPharma, Inc. recently announced the completion of its targeted enrollment for the Phase 3 INDIGO trial of its lead product candidate, obexelimab, for the…
Adragos Pharma Completes Expansion With New Ampoule Fill & Finish Line in Livron
Adragos Pharma has significantly enhanced its production capabilities with the completion of a new ampoule filling line at its Livron-sur-Drôme site in France. Adragos invested…
Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform
Araris Biotech AG recently announced the publication of a new technology for ADC generation that supports its foundational technology platform. The publication in ChemBioChem showcases,…
Enlivex Announces Enrollment & Dosing of the First 10 Patients in the Randomized Phase 2 Stage of its Allocetra Trial
Enlivex Therapeutics Ltd. recently announced the enrollment and dosing of the first 10 patients in the randomized Phase 2 stage of the company’s multi-country Phase…
Lonza to Expand Bioconjugation in Visp (CH) With Two Additional Manufacturing Suites
Lonza recently announced it will invest in additional bioconjugation capabilities in Visp (CH). The expansion will add two multipurpose 1,200L manufacturing suites and manufacturing-related infrastructure…
Gelteq Expands Operations in United States
Gelteq Limited recently announced it has expanded its operations in the United States with the appointment of Adam Bendell as President of US Operations. Gelteq…
WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development
Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….
BrainStorm Cell Therapeutics & Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing
BrainStorm Cell Therapeutics Inc. recently announced it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. through its wholly owned subsidiary (Pluri), an…
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Indaptus Therapeutics, Inc. recently announced Dr. Michael Newman, Founder and Chief Scientific Officer, has published his groundbreaking research in the peer-reviewed journal, Frontiers in Immunology.…
Can-Fite Achieves Milestone With First Patient Dosing in Pancreatic Cancer Phase 2a Clinical Trial
Can-Fite BioPharma Ltd. recently announced the dosing of the first patient in the Phase 2a clinical trial in patients with advanced pancreatic adenocarcinoma (NCT06387342). “We…
CERo Therapeutics Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
CERo Therapeutics Holdings, Inc. recently announced the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in…
WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers
This whitepaper explores the various types of technology transfer from preclinical to commercial stages and successful strategies to foster innovation.
Transgene & NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine in Head & Neck Cancer
Transgene and NEC Corporation recently announced 24.1 month median follow-up data from the ongoing randomized Phase 1 trial of TG4050 in the adjuvant treatment of head…
